{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-014729","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2025-09-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.487712+00:00","generated_at":"2026-05-17T05:49:04.071108+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MAIA Biotechnology awarded $2.3M NIH grant for THIO-101 Phase 2 trial in NSCLC","bullets":["NIH grant of $2.3M supports expansion of THIO-101 Phase 2 trial evaluating ateganosine as third-line NSCLC treatment.","Grant funds enrollment of US patients resistant to chemo/immunotherapy; distributed over 3 years (2025-2027).","First US patient enrollment to begin immediately following 2023 FDA IND clearance; first expansion patient dosed July 2025 in Taiwan.","Median overall survival for 22 third-line patients was 17.8 months (June 30, 2025) vs 5-6 months for standard chemo.","Grant is non-dilutive funding from NIH's National Cancer Institute (Award R44CA309843)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-014729","json":"https://secwatch.observer/filing/0001493152-25-014729.json","markdown":"https://secwatch.observer/filing/0001493152-25-014729.md","text":"https://secwatch.observer/filing/0001493152-25-014729.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000149315225014729/0001493152-25-014729-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000149315225014729/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:49:04.071108+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}